China SXT Pharmaceuticals, Inc.
SXTC
$1.12
-$0.04-3.45%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.70M | 1.84M | 1.97M | 2.38M | 2.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.70M | 1.84M | 1.97M | 2.38M | 2.78M |
| Cost of Revenue | 1.08M | 1.31M | 1.55M | 1.66M | 1.77M |
| Gross Profit | 625.00K | 525.60K | 426.20K | 721.70K | 1.02M |
| SG&A Expenses | 14.08M | 9.88M | 5.68M | 5.08M | 4.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.16M | 11.19M | 7.23M | 6.73M | 6.23M |
| Operating Income | -13.46M | -9.36M | -5.26M | -4.35M | -3.45M |
| Income Before Tax | -14.14M | -10.04M | -5.93M | -5.04M | -4.14M |
| Income Tax Expenses | -- | -- | -- | 1.20K | 2.40K |
| Earnings from Continuing Operations | -14.14 | -10.04 | -5.93 | -5.04 | -4.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.14M | -10.04M | -5.93M | -5.04M | -4.14M |
| EBIT | -13.46M | -9.36M | -5.26M | -4.35M | -3.45M |
| EBITDA | -13.21M | -9.11M | -5.01M | -4.11M | -3.20M |
| EPS Basic | -29.62 | -27.26 | -24.89 | -45.14 | -65.38 |
| Normalized Basic EPS | -18.01 | -16.53 | -15.05 | -27.94 | -40.83 |
| EPS Diluted | -29.62 | -27.26 | -24.89 | -45.14 | -65.38 |
| Normalized Diluted EPS | -18.01 | -16.53 | -15.05 | -27.94 | -40.83 |
| Average Basic Shares Outstanding | 1.87M | 1.47M | 1.07M | 688.30K | 308.80K |
| Average Diluted Shares Outstanding | 1.87M | 1.47M | 1.07M | 688.30K | 308.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
